[go: up one dir, main page]

DE69913548D1 - Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen - Google Patents

Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen

Info

Publication number
DE69913548D1
DE69913548D1 DE69913548T DE69913548T DE69913548D1 DE 69913548 D1 DE69913548 D1 DE 69913548D1 DE 69913548 T DE69913548 T DE 69913548T DE 69913548 T DE69913548 T DE 69913548T DE 69913548 D1 DE69913548 D1 DE 69913548D1
Authority
DE
Germany
Prior art keywords
pain
treatment
anxiety
antagonists
mglur5 antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69913548T
Other languages
English (en)
Other versions
DE69913548T2 (de
Inventor
Hans Allgeier
David Cosford
Josef Flor
Fabrizio Gasparini
Conrad Gentsch
D Hess
Carl Johnson
Rainer Kuhn
Mark Tricklebank
Laszlo Urban
Andrew Varney
Elebi Goenuel Veli
Katharine Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
SIBIA Neurosciences Inc
Original Assignee
Novartis AG
SIBIA Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69913548(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en
Application filed by Novartis AG, SIBIA Neurosciences Inc filed Critical Novartis AG
Publication of DE69913548D1 publication Critical patent/DE69913548D1/de
Application granted granted Critical
Publication of DE69913548T2 publication Critical patent/DE69913548T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
DE69913548T 1998-10-02 1999-09-30 Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen Revoked DE69913548T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9821503.1A GB9821503D0 (en) 1998-10-02 1998-10-02 Organic compounds
GB9821503 1998-10-02
US22081398A 1998-12-23 1998-12-23
US220813 1998-12-23
PCT/EP1999/007239 WO2000020001A1 (en) 1998-10-02 1999-09-30 Mglur5 antagonists for the treatment of pain and anxiety

Publications (2)

Publication Number Publication Date
DE69913548D1 true DE69913548D1 (de) 2004-01-22
DE69913548T2 DE69913548T2 (de) 2004-09-23

Family

ID=26314451

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69913548T Revoked DE69913548T2 (de) 1998-10-02 1999-09-30 Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen

Country Status (21)

Country Link
EP (1) EP1117403B1 (de)
JP (1) JP2002526408A (de)
KR (1) KR20010088832A (de)
CN (1) CN1187048C (de)
AT (1) ATE255894T1 (de)
AU (1) AU765644B2 (de)
BR (1) BR9914215A (de)
CA (1) CA2345137A1 (de)
DE (1) DE69913548T2 (de)
DK (1) DK1117403T3 (de)
ES (1) ES2213389T3 (de)
HU (1) HUP0200553A3 (de)
ID (1) ID29095A (de)
IL (2) IL142047A0 (de)
NO (1) NO20011440L (de)
NZ (1) NZ510743A (de)
PL (1) PL202906B1 (de)
PT (1) PT1117403E (de)
RU (1) RU2232017C2 (de)
SK (1) SK4382001A3 (de)
WO (1) WO2000020001A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
KR100545906B1 (ko) * 2000-12-22 2006-01-26 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ 1 길항물질로서의 테트라하이드로-(벤조 또는티에노)-아제핀-피라진 및 트리아진 유도체
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
SE0303419D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
SI2083811T1 (sl) 2006-11-22 2017-02-28 Clinical Research Associates, Llc Postopki zdravljenja Downovega sindroma, sindroma krhkega X in avtizma
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
EP2531510B1 (de) 2010-02-01 2014-07-23 Novartis AG Pyrazolo-[5,1b-]oxazol-derivate als crf-1-rezeptor-antagonisten
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EP2557183A1 (de) 2011-08-12 2013-02-13 Siemens Aktiengesellschaft Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts
MA20150428A1 (fr) 2012-05-03 2015-11-30 Novartis Ag Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline
RU2712633C1 (ru) 2015-06-03 2020-01-30 Ф. Хоффманн-Ля Рош Аг Этинильные производные
EP3661500A1 (de) 2017-07-31 2020-06-10 Novartis AG Verwendung von mavoglurant bei der reduktion des kokainkonsums oder zur verhinderung eines kokainkonsumrückfalls
EP3459939A1 (de) 2017-09-26 2019-03-27 Pragma Therapeutics Neuartige heterocyclische verbindungen als mglur7 modulatoren
KR102027368B1 (ko) * 2018-05-29 2019-10-01 서울대학교산학협력단 통증의 강도를 측정하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0334119B1 (de) * 1988-03-21 1993-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Verbindungen zur Verhinderung der Biosynthese von der Lipoxygenase abgeleiteten Metaboliten der Arachidonsäure
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives

Also Published As

Publication number Publication date
EP1117403B1 (de) 2003-12-10
DK1117403T3 (da) 2004-04-13
KR20010088832A (ko) 2001-09-28
CA2345137A1 (en) 2000-04-13
CN1187048C (zh) 2005-02-02
EP1117403A1 (de) 2001-07-25
SK4382001A3 (en) 2001-08-06
RU2232017C2 (ru) 2004-07-10
IL142047A0 (en) 2002-03-10
PL202906B1 (pl) 2009-08-31
PT1117403E (pt) 2004-04-30
HUP0200553A3 (en) 2002-11-28
BR9914215A (pt) 2001-07-03
WO2000020001A1 (en) 2000-04-13
HUP0200553A2 (hu) 2002-07-29
IL142047A (en) 2007-09-20
AU6198499A (en) 2000-04-26
ID29095A (id) 2001-07-26
NZ510743A (en) 2003-10-31
NO20011440L (no) 2001-05-15
DE69913548T2 (de) 2004-09-23
NO20011440D0 (no) 2001-03-21
AU765644B2 (en) 2003-09-25
CN1321087A (zh) 2001-11-07
ES2213389T3 (es) 2004-08-16
PL346876A1 (en) 2002-03-11
ATE255894T1 (de) 2003-12-15
JP2002526408A (ja) 2002-08-20

Similar Documents

Publication Publication Date Title
ATE255894T1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
DE60233040D1 (de) Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
ATE267595T1 (de) Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1- rezeptoren und sibutramine enthalten
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DE60140516D1 (de) Behandlung von fluorkohlenstoff- ausgangsmaterialien
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE371454T1 (de) Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
DE60102812D1 (de) Verwendung von thioamidoxazolidinonen zur behandlung von knochenresorption und osteoporose

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8331 Complete revocation